Effects of basic and dual-task training programs on physical function in Parkinson's disease: The PARKEX study.

PLoS OneSep 18, 2026 (epub)
Clinical ResearchNeurologyPhysical Medicine & Rehabilitation

Juan Carlos Magaña, Silvia Enríquez-Calzada, Roger Prat et al.

✦ AI-curated · Sources linked

In 30 seconds

The PARKEX study evaluated the effects of basic physical training (BPT) and BPT combined with dual-task functional exercises (BPT + FE) on physical function in 24 individuals with idiopathic Parkinson's disease. This randomized controlled trial found that both interventions significantly improved physical performance compared to a control group, with BPT showing a mean difference of 31.00 in the Sit-to-Stand Test.

Key findings

  • BPT improved Sit-to-Stand Test scores by a mean difference of 31.00 compared to controls (p = .0026).
  • BPT + FE improved Sit-to-Stand Test scores by a mean difference of 19.00 compared to controls (p = .0026).
  • BPT reduced Timed Up and Go times by 2.07 seconds compared to controls (p = .0039).
  • BPT + FE reduced Timed Up and Go times by 2.43 seconds compared to controls (p = .0028).

Why it matters

This study highlights the potential of exercise interventions to enhance physical performance in patients with Parkinson's disease, which may contribute to improved quality of life and functional independence.

Source

PubMed · PMID 42758697

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.